Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Empirical evidence indicates that the number of small renal lesions being identified is rising. Typically treated with nephrectomy or partial nephrectomy, Stephen Solomon shares his view on the emerging role of radiofrequency ablation and cryotherapy in the management of small renal tumors.
Following the outcome of the Prostate Cancer Prevention Trial, and with data accruing for other agents, primary chemoprevention of prostate cancer is becoming a realistic strategy for managing cancers that are identified early. The evidence relating to the different candidate agents for chemoprevention of prostate cancer is reviewed.
Despite improvements in surgical and radiotherapeutic techniques, a significant number of patients with locally advanced bladder cancer remain at a high risk of developing systemic disease. Jorge Garcia and Robert Dreicer discuss the conflicting evidence available for the use of neoadjuvant and adjuvant chemotherapy for bladder cancer.
This Drug Insight examines the mechanisms behind the antioxidant lycopene, and its association with the health promoting effects attributed to the consumption of tomatoes and tomato extracts. Data on the anticancer properties of lycopene are compelling, but it is too early to attribute all the health benefits of tomatoes to this compound.
Despite the amount of research that has gone into producing vaccines against cancer, these vaccines have yet to show clinical benefit. This article by J Vieweg and J Dannull reviews the current status of vaccination strategies for prostate cancer, and gives an update on the different stages in their development.
